

Announcement No. 18/2008

To OMX Nordic Exchange Copenhagen and the press.

Copenhagen, 2 April 2008

Exiqon A/S – Minutes of annual general meeting 2008

The annual general meeting of Exiqon A/S has been held today 2 April 2008 at Radisson SAS Scandinavia Hotel, Copenhagen, Amager Boulevard 70, 2300 København S where the general meeting resolved:

1. To approve the audited annual report,
2. To settle the losses of the year of DKK 67,623,000 by transfer to next year,
3. To re-elect Thorleif Krarup, Erik Walldén and Michael Nobel as members of the supervisory board, and to elect Per Wold-Olsen and Frank J. Kiesner as new members of the supervisory board, and
4. To re-appoint Deloitte Statsautoriseret Revisionsaktieselskab as the company's auditor.

Reference is made to the company's announcements No. 14 in 2007 and No. 10 in 2008 to OMX The Nordic Exchange Copenhagen in respect of information on Per Wold-Olsen's and Frank J Kiesner's main occupation and other material activities.

At a meeting held immediately afterwards the general meeting the supervisory board elected Thorleif Krarup as chairman of the supervisory board and Erik Walldén as vice chairman of the supervisory board. The composition of the supervisory board is, hereafter, as follows:

Thorleif Krarup, chairman
Erik Walldén, vice chairman
Michael Nobel
Per Wold-Olsen
Frank J. Kiesner

For additional information please contact

CEO Lars Kongsbak, tel. +45 4566 0888 or +45 4090 2101

CFO, Hans Henrik Chrois Christensen tel.+45 4565 0953 or +45 4090 2131

About Exiqon

Exiqon's corporate mission is to combine leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Exiqon's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon's products are based on patented technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and sensitive analysis of nucleic acids. Exiqon aims to expand the existing product offering for research use as well as to develop new proprietary molecular diagnostic products. Exiqon, through a number of recent initiatives, has positioned itself as a significant player in applying miRNA as the key biomarker in cancer diagnostics.

Disclaimer



Forward-looking statements:

This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.